A recent study reveals that individuals who come off blockbuster slimming jabs like semaglutide or tirzepatide can put back on shed pounds at a significantly accelerated pace than those who end traditional diet and exercise programs.
Published data in a prominent medical journal shows that while overweight individuals can lose about a fifth of their body weight while undergoing treatment, the weight returns at an average rate of nearly a kilo each month after stopping.
"Individuals purchasing such medications need to be informed of the potential of quick rebound weight gain when the therapy ends," warns expert Dr. Susan Jebb.
That rate of regain means a reversion to original weight in about one and a half years.
Comparing Treatments
The research, which reviewed 37 of trials involving over 9,000 of patients, contrasted the effects of these new drugs with other pills.
Researchers emphasize that individuals who lose weight through diet and exercise generally have a more gradual creep back—perhaps 100 grams monthly—post-intervention.
Understanding the Fast Regain
Nutrition scientists believe the way of the injections is key to understanding the accelerated regain.
GLP-1 drugs imitate a natural hormone called GLP-1, which moderates hunger.
"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production might result in the body to generate a reduced amount of its endogenous hormone, and may also diminish responsiveness to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication leads to appetite is uncontrolled, making binge eating much more probable."
An Ongoing Disease?
The NHS recommend the injections for people with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
Professionals contend that, given the significant potential of relapse, the treatment should be considered life-long.
This view is supported by pharmaceutical companies, who say that the findings "highlight the chronic character of obesity," comparing it to managing diseases like high blood pressure.
User Experiences
Users who have discontinued the jabs explain a intense resurgence of cravings.
"It was like a trigger activating and you're instantly ravenous," said an individual.
This challenge is compounded if patients have not adopted sustainable dietary or behavioural modifications during treatment.
Widespread Use
Survey data indicate that a significant number of people in the UK have used these injections in the past year, with interest continuing to grow.
- Adoption is higher among women compared to men.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion access the drugs through private healthcare rather than public health services.
Finally, experts stress that while these medications are potent agents for weight loss, they are not a standalone cure and long-term success relies on integrated lifestyle management.
